Loading
GC101 TIL is an experimental tumour-infiltrating lymphocyte therapy from Shanghai Juncell Therapeutics in phase 2 trials for melanoma, aimed at PD-1 and BRAF.
GC101 TIL (GC101) is a tumour-infiltrating lymphocyte therapy developed by Shanghai Juncell Therapeutics. Its targets are PD-1, BRAF and MEK1/2 (the sponsor names melanoma and non-small cell lung cancer (solid tumours)). The sponsor states: An autologous natural TIL cell therapy administered without high-intensity lymphodepleting chemotherapy and without IL-2 administration. ClinicalTrials.gov describes the intervention as: Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for r. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma. The largest, NCT06703398, plans to enrol 98 participants with primary completion was scheduled for 2026-05-12 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.GC101 TIL slips into a pocket on PD-1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"GC101 TIL" OR ABSTRACT:"GC101 TIL" OR TITLE:"GC101" OR ABSTRACT:"GC101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GC101 TIL, not a curated reading list.
Shares BRAF and the tag pipeline.
Shares MEK1/2 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.